REGENXBIO (NASDAQ:RGNX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of REGENXBIO (NASDAQ:RGNX) from a strong sell rating to a hold rating in a report published on Saturday.

RGNX has been the topic of a number of other reports. Barclays downgraded shares of REGENXBIO from an “overweight” rating to a “hold” rating in a research report on Friday. Morgan Stanley reaffirmed an “overweight” rating and issued a $18.00 target price on shares of REGENXBIO in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of REGENXBIO in a report on Wednesday, July 1st. Zacks Research cut shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Finally, Leerink Partners boosted their price target on shares of REGENXBIO from $17.00 to $18.00 and gave the company an “outperform” rating in a report on Monday, June 22nd. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

REGENXBIO Stock Down 5.0%

Shares of REGENXBIO stock opened at $10.72 on Friday. The business has a fifty day simple moving average of $10.02 and a 200 day simple moving average of $9.43. The stock has a market cap of $554.22 million, a PE ratio of -2.83 and a beta of 0.94. REGENXBIO has a 12 month low of $5.45 and a 12 month high of $16.19.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.35. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%.The firm had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million. Analysts expect that REGENXBIO will post -3.96 EPS for the current fiscal year.

Insider Activity at REGENXBIO

In related news, insider Steve Pakola sold 2,161 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $13.64, for a total value of $29,476.04. Following the sale, the insider directly owned 213,009 shares of the company’s stock, valued at approximately $2,905,442.76. The trade was a 1.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 73,803 shares of company stock worth $886,937 in the last quarter. Company insiders own 14.22% of the company’s stock.

Hedge Funds Weigh In On REGENXBIO

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of REGENXBIO during the 2nd quarter worth approximately $76,641,000. AQR Capital Management LLC lifted its position in shares of REGENXBIO by 2,247.7% in the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after purchasing an additional 594,161 shares in the last quarter. State Street Corp boosted its holdings in REGENXBIO by 15.2% during the fourth quarter. State Street Corp now owns 2,286,736 shares of the biotechnology company’s stock worth $32,929,000 after purchasing an additional 301,858 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in REGENXBIO during the first quarter worth $2,305,000. Finally, GSK plc bought a new position in REGENXBIO in the fourth quarter valued at $3,909,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO News Roundup

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Strong Q2 results: REGENXBIO reported earnings of $0.43 per share, well above analyst estimates of $0.08–$0.12, while revenue of $108.0 million exceeded the $97.6 million consensus estimate. The result compares with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Key pipeline milestones remain on track: The company said its RGX-202 gene therapy filing for Duchenne muscular dystrophy is expected to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. RGX-121 for Hunter syndrome is also targeted for resubmission in Q3 2026, while pivotal wet age-related macular degeneration data are expected in Q4 2026. REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Improved financial flexibility: More than $200 million of new capital raised in July increased pro forma cash, cash equivalents and marketable securities to over $310 million and extended the cash runway into the fourth quarter of 2027. This reduces near-term financing pressure as the company advances its programs. REGENXBIO Outlines Cash Runway
• Neutral Sentiment: Barclays maintained an Equal Weight rating and set a $12 price target, implying potential upside from recent trading levels but signaling a balanced view rather than a strong bullish recommendation. Barclays Rating Update
• Negative Sentiment: Profitability remains weak: Despite the quarterly beat, REGENXBIO continues to report a deeply negative net margin and return on equity, and analysts expect a full-year loss. Investors may therefore view the earnings improvement as less durable if it depends on licensing or other non-recurring revenue.
• Negative Sentiment: Material execution risk remains: The stock’s valuation and future upside depend heavily on successful regulatory filings, clinical data and eventual commercialization of its gene-therapy programs. Delays, safety concerns or disappointing trial results could pressure RGNX.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.